Wonder if CytoDyns Lawyers are ready to take on AF
Post# of 148114
TWEETED BY Adam Feuerstein
$CYDY leronlimab ph3 study in patients w/ severe Covid19 failed its primary endpoint - improvement in mortality. As with its previous failed study in moderate Covid, the company is spinning the data to cushion the blow of a negative outcome.